The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes
Open accessAbstract
Strong epidemiologic evidence suggests an association between Alzheimer disease (AD) and type 2 diabetes. To determine if amyloid beta (Aβ) and hyperphosphorylated tau occurs in type 2 diabetes, pancreas tissues from 21 autopsy cases (10 type 2 diabetes and 11 controls) were analyzed. APP and tau mRNAs were identified in human pancreas and in cultured insulinoma beta cells (INS-1) by RT-PCR. Prominent APP and tau bands were detected by Western blotting in pancreatic extracts. Aggregated Aβ, hyperphosphorylated tau, ubiquitin, apolipoprotein E, apolipoprotein(a), IB1/JIP-1 and JNK1 were detected in Langerhans islets in type 2 diabetic patients. Aβ was co-localized with amylin in islet amyloid deposits. In situ beta sheet formation of islet amyloid deposits was shown by infrared microspectroscopy (SIRMS). LPS increased APP in non-neuronal cells as well. We conclude that Aβ deposits and hyperphosphorylated tau are also associated with type 2 diabetes, highlighting common pathogenetic features in neurodegenerative disorders, including AD and type 2 diabetes and suggesting that Aβ deposits and hyperphosphorylated tau may also occur in other organs than the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Cooper, G. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8628 · Cited by 1,299 · cited 7×
“Amyloidogenicity and cytotoxicity of recombinant mature human islet amyloid polypeptide (rhIAPP).”
BackgroundInfluentialDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 1×
“Conversely, patients ith type 2 diabetes have twice the risk of controls to develop D (Arvanitakis et al., 2004; Grodstein et al., 2001; Leibson t al., 1997; Ott et al., 1999; Peila et al., 2002; Xu et al., 2004).”
BackgroundType 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207 · cited 1×
“Conversely, patients ith type 2 diabetes have twice the risk of controls to develop D (Arvanitakis et al., 2004; Grodstein et al., 2001; Leibson t al., 1997; Ott et al., 1999; Peila et al., 2002; Xu et al., 2004).”
BackgroundIncreased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950
Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802 · cited 1×
“…been reports of Apo-E asso- I c r l 55 cm ) showed an absorbance maximum near 1630 cm representative amyloid, the absorbance maximum was near 1655 cm−1 corresponding to iation with amyloid deposits independently of the primary myloid protein (Wisniewski and Frangione, 1992; Charge et l., 1996).”
BackgroundRisk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700
Cited by
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Verdile, G., Keane, K. N., Cruzat, V. F., Medic, S., Sabale, M., Rowles, J., Wijesekara, N., Martins, R. N., Fraser, P. E., & Newsholme, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/105828 · Cited by 495
Self-citationAlzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2025) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 410
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Type 2 diabetes as a protein misfolding disease
Mukherjee, A., Morales-Scheihing, D., Butler, P. C., & Soto, C. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.005 · Cited by 342
Metadata
- Authors
- Miklossy, J., Qing, H., Radenovic, A., Kis, A., Vileno, B., Làszló, F., Miller, L., Martins, R. N., Waeber, G., Mooser, V., Bosman, F., Khalili, K., Darbinian, N., & McGeer, P. L.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 31
- Issue
- 9
- Pages
- 1503-1515
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2109241488
- Cited by
- 235
- References
- 8
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.